Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Kathryn Kreider

Nurse Practitioner Durham, NC Nurse Practitioner

NPI 1467691659 CMS profile 10445403

2100 Erwin Rd, Durham, NC 27710

Open in the dashboard

General payments

$12,576

20 records reported · program years 2021–2025

Research payments

$410

Paid to them · 1 record reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kathryn Kreider of Durham, NC is reported in the CMS Open Payments database as having received $12,576 across 20 general payments and $410 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,332 4
2024 General $90 1
2023 General $362 3
2023 Research $410 1
2022 General $6,572 5
2021 General $4,220 7

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kathryn Kreider
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Kathryn Kreider were reported at $1,332. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Kathryn Kreider Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $4,220 $135 $40–$426 $132
2022 $6,572 $152 $48–$470 $149
2023 $362 $166 $54–$529 $160
2024 $90 $173 $55–$556 $164
2025 $1,332 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Novo Nordisk Inc $10,913 13 payments
  2. Madrigal Pharmaceuticals $1,241 3 payments
  3. Horizon Therapeutics plc $125 1 payment
  4. Dexcom, Inc. $115 1 payment
  5. Sanofi-Aventis U.S. LLC $91 1 payment
  6. Abbott Laboratories $90 1 payment

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Consulting Fee $9,201 6 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $1,955 2 payments
  3. Food and Beverage $1,327 9 payments
  4. Education $65 2 payments
  5. Travel and Lodging $28 1 payment
Products named General payments · program years 2021–2025
  1. RYBELSUS $3,764 4 payments
  2. REZDIFFRA $1,241 3 payments
  3. Ozempic $516 2 payments
  4. TEPEZZA $125 1 payment
  5. Wegovy $122 1 payment
  6. DEXCOM G7 GSS (161) $115 1 payment
  7. TZIELD $91 1 payment
  8. FreeStyle Libre 3 $90 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2021–2025
  1. Dexcom, Inc. $410 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 32 drugs

Part D claims

923

Median for Nurse Practitioner: 389

Drug cost

$422,557

Median for Nurse Practitioner: $21,885

Branded share of claims

60.7%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 56 $81,357
Jardiance Empagliflozin Brand 62 $65,213
Mounjaro Tirzepatide Brand 35 $61,881
Repatha Sureclick Evolocumab Brand 49 $48,855
Omnipod 5 Dexg7g6 Pods (Gen 5) Insulin Pump Cart,auto,bt,g6/7 Brand 25 $27,017
Praluent Pen Alirocumab Brand 27 $26,080
Rybelsus Semaglutide Brand 16 $23,272
Trulicity Dulaglutide Brand 19 $22,878
Tresiba Flextouch U-100 Insulin Degludec Brand 22 $11,667
Vascepa Icosapent Ethyl Brand 16 $8,969

The 10 drugs with the highest cost, of 32 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 16 billing codes

Paid by Medicare

$8,673

Medicare's payments for the services billed

Medicare patients

65

Average age 71

Services billed

183

41 women, 24 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 63%
Arthritis 51%
Chronic kidney disease 43%
Ischemic heart disease 40%
Atrial fibrillation 31%
Depression 29%
Heart failure 25%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

21 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record